Trial Profile
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Idasanutlin (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 22 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 19 May 2020 Planned End Date changed from 30 Apr 2020 to 31 May 2020.
- 19 May 2020 Planned primary completion date changed from 30 Apr 2020 to 31 May 2020.